Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MULTISARC: Molecular Profiling of Advanced Soft-Tissue Sarcomas
2024-514873-22-00Phase 3Completed
- Sponsor
- Inserm
- Start
- Oct 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of olaparib, palbociclib, durvalumab, capmatinib, glasdegib and 6 more in soft tissue sarcoma (STS) (2 arms), sponsored by Inserm. Primary endpoint: Feasibility of next generation sequencing exome. Started Oct 2024; status: completed.
02
Drugs
olaparibpalbociclibdurvalumabcapmatinibglasdegib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-514873-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514873-22-00.